Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -11.16% is 98% above its 5-year average of -514.61%, near the high end of its 5-year range (-4382.24%–1340.67%).
99.15% above its 12-month average of -1308.87%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -701.65%.
OPERATING MARGIN
-11.16%
OPERATING MARGIN AVG TTM
-1308.87%
OPERATING MARGIN AVG 3Y
-538.62%
OPERATING MARGIN AVG 5Y
-514.61%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.15%
CURRENT VS 3Y AVG
+97.93%
CURRENT VS 5Y AVG
+97.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Stoke Therapeutics, Inc.
Market Cap
$1.57B
Operating Margin
-11.16%
TTM Avg
-1308.87%
3Y Avg
-538.62%
5Y Avg
-514.61%
Market Cap
$1.59B
Operating Margin
-134.48%
TTM Avg
-159.75%
3Y Avg
-419.83%
5Y Avg
-335.87%
Market Cap
$1.60B
Operating Margin
-1166.77%
TTM Avg
-923.17%
3Y Avg
-941.56%
5Y Avg
-673.55%
Market Cap
$1.54B
Operating Margin
-158.45%
TTM Avg
-796.44%
3Y Avg
-398.22%
5Y Avg
-1047.05%
Market Cap
$1.61B
Operating Margin
-521.04%
TTM Avg
-395.30%
3Y Avg
-271.08%
5Y Avg
-270.79%
Market Cap
$1.54B
Operating Margin
36.66%
TTM Avg
42.52%
3Y Avg
46.05%
5Y Avg
62.54%
Market Cap
$1.61B
Operating Margin
-175.83%
TTM Avg
-3847.13%
3Y Avg
-1580.02%
5Y Avg
-1580.02%
Market Cap
$1.62B
Operating Margin
-5.55%
TTM Avg
-16.51%
3Y Avg
-27.71%
5Y Avg
-34.02%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | $1.57B | -11.16% | -1308.87% | -538.62% | -514.61% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -134.48% | -159.75% | -419.83% | -335.87% |
| uniQure N.V. (QURE)vs › | $1.60B | -1166.77% | -923.17% | -941.56% | -673.55% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -158.45% | -796.44% | -398.22% | -1047.05% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -521.04% | -395.30% | -271.08% | -270.79% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 36.66% | 42.52% | 46.05% | 62.54% |
| Septerna Inc (SEPN)vs › | $1.61B | -175.83% | -3847.13% | -1580.02% | -1580.02% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 4.73% | 0.51% | -0.21% | 1.84% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -5.55% | -16.51% | -27.71% | -34.02% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 15.35% | 4.65% | 1.95% | -3.05% |
Gross Margin
100.0%
Operating Margin
-11.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -701.65% |
| 2026-03-31 | -857.57% |
| 2025-12-31 | -4382.24% |
| 2025-09-30 | -405.30% |
| 2025-06-30 | -197.58% |
| 2025-03-31 | 70.15% |
| 2024-12-31 | -60.37% |
| 2024-09-30 | -613.06% |
| 2024-06-30 | -607.37% |
| 2024-03-31 | -672.96% |
| 2023-12-31 | -1055.89% |
| 2023-09-30 | -823.28% |
| 2023-06-30 | 1340.67% |
| 2023-03-31 | -479.23% |
| 2022-12-31 | -831.29% |
| 2022-09-30 | -934.53% |
| 2022-06-30 | -781.12% |
| 2022-03-31 | -826.50% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
